Omeros Corp at Bank of America NAPA Healthcare Conference (Virtual) Transcript
Hi, everyone. Welcome to day 2 of the Virtual Napa Conference here at Bank of America. I'm Greg Harrison, one of the analysts on the biotech team. And on behalf of myself and Geoff Meacham, we'd like to welcome Greg Demopulos, CEO of Omeros. We'll jump into Q&A in a moment, but Greg, if you want to make any opening comments, please do so now.
Yes. Thanks, Greg, to you and Geoff and the rest of the team at BofA. We're appreciative of the opportunity to join you folks today. So thanks.
Questions & Answers
Great. So your lead program is a complement inhibitor targeting MASP-2 in lectin pathway. Maybe you can just give an overview of the advantages that you see from your end, looking upstream within complement as opposed to other assets that target later in the cascade like C2 or
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |